accueil

Sofinnova Partners is a leading European venture capital firm specialized in Life Sciences. Based in Paris, France, with offices in London and Milan, the firm brings together a team of over 40 professionals from all over Europe, the U.S., and Asia. 

The firm focuses on paradigm-shifting technologies alongside visionary entrepreneurs. Sofinnova Partners invests across the Life Sciences value chain as a lead or cornerstone investor, from very early-stage opportunities to late-stage/public companies. It has backed over 500 companies over five decades, creating market leaders around the globe. Today, Sofinnova Partners has over €2 billion under management.

Sofinnova Partners invest in start-ups, early-stage companies, corporate spin-offs, and occasionally turnaround situations. The firm invests in Life Sciences (Biopharmaceuticals / Biotech, Medical Devices, Industrial Biotechnology). Sofinnova Partners proactively sources deals, takes a lead role, is most often the first institutional investor in Round A financings, and leads its portfolio companies until exit. The firm's partners sit on the boards of its portfolio companies and play an active role in the formation phase alongside entrepreneurs. Sofinnova Partners invests throughout Europe from its headquarters in Paris with a portion of investments made in the rest of the world.

View More

Data from Phase 1 Trial of RGX-202 Presented at 2020 ASCO Virtual Scientific Program   May 29, 2020 08:02 AM Eastern Daylight Time   NEW YORK--(BUSINESS WIRE)--RGENIX, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule an...

HAYWARD, Calif., May 28, 2020 – RefleXion Medical, a therapeutic oncology company pioneering biology-guided radiotherapy* (BgRT) for treating all stages of cancer, today announced a clinical collaboration with Merck (known as MSD outside the U.S. and Canada) t...

Funding will enable accelerated development of a proprietary platform for the industrial production of Biotalys’ protein-based biocontrols   GHENT, Belgium, May 26, 2020 (GLOBE NEWSWIRE) -- Biotalys NV, a transformative food and crop protection company, today ...

Second regulator to approve "miR-AGE" Phase 2b/3 trial after clearance of French authorities (ANSM)   1,034-patient placebo-controlled trial to test oral ABX464's triple effect in COVID-19 patients: antiviral, anti-inflammatory and tissue repair Bpifrance prov...

Arrabina™ Arabinoxylan GI tolerance no different than placebo   SCHAUMBURG, Ill., May 20, 2020 /PRNewswire/ -- Comet Bio announced today the successful completion of its randomized, placebo-controlled, crossover clinical trial evaluating the gastrointestinal (...

Maina Bhaman

Maina Bhaman

Partner, Capital Funds

MEET OUR TEAM